Table 1

Cerebellar cortical thickness in HC and ALS-NEG and ALS-C9

Cerebellar cortical thicknessEstimated marginal mean±SE for groupsStatistics
Controls, n=110ALS-NEG, n=133ALS-C9, n=22Univariate effect sizeHC vs ALS-NEGHC vs ALS-C9
Left
lobules*
I–II1.423±0.0361.506±0.0331.541±0.080η2p=0.0140.2730.525
III3.221±0.0363.225±0.0333.248±0.081η2p=0.0001.0001.000
IV4.916±0.0144.894±0.0134.812±0.032η2p=0.0340.764 0.009
V4.899±0.0174.893±0.0154.780±0.037η2p=0.0331.000 0.012
VI4.979±0.0114.963±0.0104.881±0.025η2p=0.0480.849 0.001
VIIB4.605±0.0214.595±0.0194.522±0.046η2p=0.0101.0000.307
VIIIA4.651±0.0174.682±0.0164.674±0.039η2p=0.0070.5521.000
VIIIB4.522±0.0334.533±0.0304.509±0.073η2p=0.0001.0001.000
IX3.570±0.0443.588±0.0403.449±0.099η2p=0.0061.0000.784
X2.499±0.0442.511±0.0402.561±0.099η2p=0.0011.0001.000
Crus I4.571±0.0214.499±0.0194.386±0.046η2p=0.058 0.032 0.001
Crus II4.358±0.0244.314±0.0224.169±0.054η2p=0.0380.549 0.005
Right
lobules†
I–II1.362±0.0341.453±0.0311.538±0.076η2p=0.0240.1500.104
III3.097±0.0333.156±0.0303.183±0.074η2p=0.0080.5840.869
IV4.777±0.0174.759±0.0164.739±0.039η2p=0.0041.0001.000
V4.756±0.0184.731±0.0164.650±0.040η2p=0.0220.930 0.049
VI4.930±0.0114.914±0.0104.847±0.025η2p=0.0350.901 0.007
VIIB4.789±0.0164.751±0.0144.620±0.035η2p=0.0700.240 <0.001
VIIIA4.645±0.0174.646±0.0154.599±0.037η2p=0.0061.0000.763
VIIIB4.580±0.0264.600±0.0244.492±0.059η2p=0.0111.0000.530
IX3.765±0.0393.807±0.0353.658±0.087η2p=0.0101.0000.778
X2.254±0.0382.154±0.0342.159±0.084η2p=0.0150.1620.921
Crus I4.634±0.0204.576±0.0184.494±0.045η2p=0.0360.109 0.015
Crus II4.574±0.0214.527±0.0194.413±0.046η2p=0.0400.287 0.005
  • Estimated marginal mean±SE for cortical thickness adjusted for age and gender.

  • Bold p values are significant at p<0.05 after Bonferroni correction for multiple comparisons.

  • Partial η2 effect size is interpreted as small (η2p=0.01), medium (η2p=0.06) or large (η2p=0.14).

  • *Wilks’ lambda=0.828; F=2.055; p=0.001; η2p=0.090.

  • †Wilks’ lambda=0.821; F=2.146; p=0.001; η2p=0.94.

  • ALS, amyotrophic lateral sclerosis; ALS-C9, patients who tested positive for GGGGCC repeat expansions in C9orf72; ALS-NEG, patients who tested negative for both ATXN2 and C9orf72; HC, healthy control.